Connor Clark & Lunn Investment Management Ltd. Acquires New Holdings in Celcuity, Inc. $CELC

Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Celcuity, Inc. (NASDAQ:CELC) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 91,449 shares of the company’s stock, valued at approximately $9,567,000.

Other hedge funds have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC lifted its stake in Celcuity by 1,329.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after buying an additional 319 shares in the last quarter. US Bancorp DE increased its position in shares of Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after acquiring an additional 143 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Celcuity by 78.9% during the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after acquiring an additional 1,167 shares during the period. Parallel Advisors LLC acquired a new stake in shares of Celcuity during the first quarter worth $38,000. Finally, Meeder Asset Management Inc. acquired a new stake in shares of Celcuity during the fourth quarter worth $42,000. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Celcuity Stock Up 3.0%

Celcuity stock opened at $95.08 on Thursday. The company has a market cap of $4.65 billion, a P/E ratio of -22.11 and a beta of 0.20. Celcuity, Inc. has a 1-year low of $44.42 and a 1-year high of $151.02. The company has a fifty day simple moving average of $94.52 and a 200 day simple moving average of $107.38. The company has a current ratio of 8.93, a quick ratio of 8.93 and a debt-to-equity ratio of 6.04.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.28). Research analysts anticipate that Celcuity, Inc. will post -4.75 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on CELC shares. Leerink Partners set a $155.00 target price on shares of Celcuity in a research note on Tuesday, June 2nd. Guggenheim lifted their price target on Celcuity from $165.00 to $175.00 and gave the company a “buy” rating in a research note on Monday, August 17th. Weiss Ratings upgraded Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. Stifel Nicolaus reduced their price objective on Celcuity from $175.00 to $150.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Finally, Craig Hallum reiterated a “buy” rating and set a $178.00 price objective on shares of Celcuity in a report on Wednesday, July 15th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Celcuity presently has an average rating of “Moderate Buy” and an average target price of $154.55.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.